Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

9 terminated/withdrawn out of 45 trials

Success Rate

59.1%

-27.4% vs industry average

Late-Stage Pipeline

2%

1 trials in Phase 3/4

Results Transparency

54%

7 of 13 completed trials have results

Key Signals

13 recruiting7 with results8 terminated

Enrollment Performance

Analytics

Phase 1
26(57.8%)
Phase 2
17(37.8%)
Phase 3
1(2.2%)
Early Phase 1
1(2.2%)
45Total
Phase 1(26)
Phase 2(17)
Phase 3(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (45)

Showing 20 of 45 trials
NCT05200442Phase 1Suspended

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

Role: collaborator

NCT04331041Phase 2Active Not Recruiting

Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

Role: collaborator

NCT05608252Phase 1Recruiting

VS-6766+Abema+Fulv in Met HR+/HER- BC

Role: collaborator

NCT05787561Phase 2Recruiting

A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer

Role: collaborator

NCT06394804Phase 2Recruiting

A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer

Role: collaborator

NCT07020221Phase 1Recruiting

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Role: lead

NCT07126158Phase 2Recruiting

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

Role: collaborator

NCT06072781Phase 3Recruiting

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Role: lead

NCT06007924Phase 2Recruiting

A Study of Avutometinib and Defactinib in People With Thyroid Cancer

Role: collaborator

NCT03875820Phase 1Active Not Recruiting

Phase I Trial of Defactinib and VS-6766.

Role: collaborator

NCT03727880Phase 2Completed

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

Role: collaborator

NCT02407509Phase 1Completed

Phase I Trial of VS-6766 Alone and in Combination With Everolimus

Role: collaborator

NCT06630260Phase 1Recruiting

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours

Role: collaborator

NCT05074810Phase 1Active Not Recruiting

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Role: lead

NCT07318324Phase 1Not Yet Recruiting

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

Role: collaborator

NCT06682572Phase 2Active Not Recruiting

A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients

Role: lead

NCT05798507Early Phase 1Active Not Recruiting

Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma

Role: collaborator

NCT06194929Phase 1Recruiting

Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

Role: collaborator

NCT06487221Phase 2Recruiting

Avutometinib and Defactinib in Diffuse Gastric Cancer

Role: collaborator

NCT05512208Phase 2Recruiting

A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

Role: collaborator